Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).

Saved in:
Bibliographic Details
Title: Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Authors: Issa GC; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Aldoss I; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Thirman MJ; Biological Sciences Division, The University of Chicago Medicine, Chicago, IL., DiPersio J; John T. Milliken Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO., Arellano M; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA., Blachly JS; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH., Mannis GN; Division of Hematology, Stanford University School of Medicine, Stanford, CA., Perl A; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Dickens DS; University of Iowa Stead Family Children's Hospital, Iowa City, IA., McMahon CM; UCHealth Blood Disorders and Cell Therapies Center, University of Colorado School of Medicine, Aurora, CO., Traer E; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Zwaan CM; Princess Máxima Center for Pediatric Oncology, Utrecht, and Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands., Grove CS; Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia., Stone R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Shami PJ; University of Utah Huntsman Cancer Institute, Salt Lake City, UT., Mantzaris I; Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY., Greenwood M; Department of Haematology, Royal North Shore Hospital, The University of Sydney, Sydney, New South Wales, Australia., Shukla N; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Cuglievan B; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Kovacsovics T; City of Hope Phoenix, Goodyear, AZ., Gu Y; Syndax Pharmaceuticals, Inc, Waltham, MA., Bagley RG; Syndax Pharmaceuticals, Inc, Waltham, MA., Madigan K; Syndax Pharmaceuticals, Inc, Waltham, MA., Chudnovsky Y; Syndax Pharmaceuticals, Inc, Waltham, MA., Nguyen HV; Syndax Pharmaceuticals, Inc, Waltham, MA., McNeer N; Syndax Pharmaceuticals, Inc, Waltham, MA., Stein EM; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Jan; Vol. 43 (1), pp. 75-84. Date of Electronic Publication: 2024 Aug 09.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO.24.00826